Federal Project Grant Award Summary

Remedi, Inc. received a $293,684 Project Grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273), awarded July 20, 2026, with completion targeted for June 30, 2027. The project focuses on developing an enhanced oral formulation of dimethyltryptamine (DMT) co-formulated with CX157, a proprietary reversible and selective monoamine oxidase-A (MAO-A) inhibitor, to address critical pharmacokinetic limitations that currently prevent oral administration of DMT. This innovation is designed to deliver a therapeutic intervention for alcohol use disorder (AUD), a condition affecting over 10% of the U.S. population with existing treatment options demonstrating limited efficacy and high relapse rates.

The research addresses a significant treatment gap by leveraging emerging evidence that serotonergic psychedelics offer promise for addiction treatment with potentially longer-lasting effects than conventional pharmaceuticals. By enabling reliable oral bioavailability of DMT through reversible MAO-A inhibition rather than alternative routes such as inhalation or infusion, the co-formulation aims to reduce administration variability, patient distress, and abuse potential while maintaining tolerability through selective targeting of the MAO-A enzyme. The work is being conducted at Remedi, Inc.'s facility in Norwell, Massachusetts.